BioSpace News Archive

Aura Biosciences Inc. (NASDAQ: AURA), today announced multiple presentations of data evaluating its first VDC candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma [indeterminate lesions and small choroidal melanoma (IL/CM)].

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the H.C. Wainwright 24th Annual Global Investment Conference.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an automated RV/LV ratio algorithm, a seamless new component of the Viz PE Solution.

Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics, announced that it has completed the second and final tranche of its previously announced private placement with Evotec SE of 2,709,800 common shares of the Company at a price of $2.50 per share for total proceeds of $6,774,500.

BIONIK Laboratories Corp. announced that Richard Russo, Interim CEO, will present a corporate overview at the National Investment Banking Association conference on September 8, 2022.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today announced that Paratek President and Chief Commercial Officer Adam Woodrow will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference.

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, announced participation in upcoming investor conferences.

Applied Genetic Technologies Corporation announced that management will be participating in the following investor conferences.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced the acceptance of a late-breaking oral presentation and an additional poster presentation, including Phase 2a data for AZP-3601, its lead therapeutic peptide for hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting.

Arcutis Biotherapeutics, Inc., an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, announced that Arcutis management will participate in an upcoming investor conference.